Physician profile
Michelle Barthe
NPI 1952706947
$501.45
in general payments reported to CMS, 2019-2025
13 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.62 · 2023: $120 · 2024: $18.04 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.61 | 2025 | Ozempic, Rybelsus |
| Intuitive Surgical, INC. | $84.94 | 2025 | |
| Pfizer INC. | $49.78 | 2023-2025 | |
| Astellas Pharma US INC | $43.98 | 2025 | Veozah |
| Amgen INC. | $37.49 | 2023-2025 | Repatha, Repatha, Otezla |
| United Therapeutics Corporation | $33.81 | 2023 | Tyvaso |
| Lilly USA, LLC | $30.97 | 2025 | Zepbound, Mounjaro |
| Ultragenyx Pharmaceutical INC. | $25.35 | 2023 | Crysvita |
| Corcept Therapeutics | $21.20 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.67 | 2025 | Xifaxan |
| Lexicon Pharmaceuticals, INC. | $19.90 | 2023 | Inpefa |
| Dexcom, INC. | $15.13 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Barthe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.